Trending Tickers: $CRWV Acquires $CORZ, $PLUG Extends Key Deal, $PROK Reports Positive Trial Data
This week, several stocks caught investors’ attention, driven by significant developments and market momentum. Here’s the breakdown of this week’s trending stocks:
CoreWeave ($CRWV) to Acquire Core Scientific ($CORZ) in $9B All-Stock Deal
CoreWeave ($CRWV), a cloud platform provider for AI and high-performance computing workloads, has announced a definitive agreement to acquire digital infrastructure firm Core Scientific ($CORZ) in an all-stock transaction valued at approximately $9 billion. Under the deal, Core Scientific shareholders will receive 0.1235 shares of CoreWeave Class A stock for each $CORZ share.
According to the companies, the acquisition will allow CoreWeave to bring its data center footprint in-house, gaining control of roughly 1.3 gigawatts of gross power capacity with the potential to expand by another 1 GW. CoreWeave said the deal will eliminate over $10 billion in future lease overhead and generate $500 million in estimated annual cost savings by the end of 2027. The company is also exploring options to repurpose or divest Core Scientific’s crypto mining assets.
Core Scientific operates ten large-scale data centers across seven U.S. states and has been shifting its infrastructure toward AI-related colocation contracts. CoreWeave went public earlier this year and has seen rapid growth in demand for AI-focused cloud solutions.
Stock Price Reaction
$CRWV traded slightly lower, reflecting investor concerns about potential dilution and integration risks.
$PLUG Extends Hydrogen Supply Deal
Plug Power Inc. ($PLUG), a U.S.-based hydrogen solutions provider serving over 275 hydrogen-consuming customer sites, has announced a multi-year extension of its supply agreement with a longtime U.S. industrial gas partner. According to the company, the deal secures liquid hydrogen supply through 2030 while immediately lowering costs and enhancing network efficiency. Plug said the agreement aligns with its broader efforts to improve margins and cash flow as part of Project Quantum Leap, a company-wide cost optimization initiative. The company also highlighted that the deal supports its ongoing infrastructure rollout, including over 40 new hydrogen sites in 2025 and production facilities already operating in Georgia, Tennessee, and Louisiana.
Stock Price Reaction
Shares of $PLUG rose 25.4% on the day of the announcement.
$PROK Shares Surge on Positive Kidney Trial Results
ProKidney ($PROK), a biotech company developing cell therapies for chronic kidney disease (CKD), reported strong results from its Phase 2 REGEN-007 trial. In the main group of patients, the decline in kidney function slowed by 78% after two injections of rilparencel, the company’s lead therapy. A second group receiving fewer injections saw a 50% improvement, suggesting a possible dose response. According to the company, no serious side effects were reported, and the therapy’s safety was comparable to a routine kidney biopsy. ProKidney plans to meet with the FDA this summer to discuss using this data for accelerated approval of its ongoing Phase 3 trial.
Stock Price Reaction
$PROK stock jumped 16% on the day of the announcement.
This article is for informational purposes only and is not investment advice or a solicitation to buy or sell securities. The content is based on publicly available information and reflects the author’s opinions as of the publication date, which may change without notice. All investments carry inherent risks, including the potential loss of principal, and past performance is not indicative of future results. Forward-looking statements, including references to projected revenues, market trends, or business developments, are based on current expectations and assumptions. Actual results may differ due to various factors, including regulatory changes, economic conditions, competitive pressures, and unforeseen market fluctuations. Readers should conduct their own research or consult a financial advisor before making investment decisions. BBAE holds no position in the securities mentioned, nor are they compensated by the companies mentioned.
